Zyflo (Zileuton)
Purpose of Medication and Method of Action
Zyflo originally approved in 1996 and marketed by Abbott was withdrawn from the market in 2004. Zyflo is a specific inhibitor of 5-lipoxygenase and thus inhibits leukotriene (LTB4, LTC4, LTD4, and LTE4) formation. These mediators are important in bronchial inflammation which precipitates
Asthmatic attacks.
Patient Medication Information
These information sheets do not list all known side effects of the medications, only the most common side effects. For a complete list of side effects please contact your local pharmacy or the actual drug manufacturing company.